Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 11/20 | 0.64 |
| ▸ | PYGM | P11217 | 9/20 | 0.64 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29900499 | 1.00 | PYGL (0.64) | PYGLPYGMRIPK1GAAMAPT | |
| SCHEMBL15541576 | 1.00 | PYGL (0.64) | PYGLPYGMRIPK1GAAMAPT | |
| SCHEMBL2837105 | 0.86 | PYGL (0.60) | PYGLPYGMRIPK1BRD4CREBBP | |
| SCHEMBL1976547 | 0.85 | PYGL (0.66) | PYGLPYGMRIPK1 | |
| SCHEMBL4216634 | 0.85 | PYGL (0.66) | PYGLPYGMRIPK1 | |
| SCHEMBL4232147 | 0.85 | PYGL (0.66) | PYGLPYGMRIPK1 | |
| SCHEMBL22469203 | 0.82 | PYGL (0.57) | PYGLPYGMRIPK1MAPT | |
| SCHEMBL11959858 | 0.82 | PYGL (0.69) | PYGLPYGMRIPK1 | |
| SCHEMBL8916097 | 0.82 | PYGL (0.69) | PYGLPYGMRIPK1 | |
| SCHEMBL4390484 | 0.82 | PYGL (0.46) | PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | CISTIM LEUVEN VZW (BE) | 2024-01-25 | — | — | US | disclosed |
| US-20230278962-A1 | Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-09-07 | — | — | US | disclosed |
| EP-4222143-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | Katholieke Universiteit Leuven (BE) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025856-A1 | 1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AS INHIBITORS OF THE YAP/TAZ-TEAD ACTIVATION FOR TREATING CANCER | YAP1, TEAD2, TEAD1 | PYGL 449/4885PYGM 2161/4885RIPK1 1424/4885 |
| US-20230278962-A1 | Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD | YAP1, TEAD2, TEAD4 | PYGL 614/4885PYGM 2664/4885RIPK1 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.